PDEX PRO DEX INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 788920 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.3%
TTM net income YoY7.5%
TTM EPS YoY9.6%
Revenue 3-yr CAGR19.2%
Net income 3-yr CAGR16.7%
Margins
Gross margin32.5%
Operating margin16.8%
Net margin15.1%
FCF margin13.4%
EBITDA margin18.7%
Returns
ROE26.5%
ROA17.1%
ROIC (approx.)27.0%
Asset turnover1.13x
Leverage & solvency
Liabilities / assets35.6%
Debt / equity0.00x
Current ratio4.19x
Interest coverage15.36x
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio0.9%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $77.55M | $66.59M |
| Cost of revenue | $53.21M | $47.08M |
| Gross profit | $24.34M | $19.51M |
| R&D expense | $3.35M | $3.64M |
| SG&A expense | $8.00M | $5.18M |
| Operating income | $12.99M | $10.69M |
| Interest expense | $812,000 | $829,000 |
| Pretax income | $18.02M | $12.06M |
| Income tax | $4.35M | $3.08M |
| Net income | $13.66M | $8.98M |
| EBITDA | $14.38M | $11.93M |
| EPS (basic) | 4.24 | 2.73 |
| EPS (diluted) | 4.12 | 2.67 |
| Weighted avg. shares (diluted) | 3.32M | 3.36M |
| Balance sheet | ||
| Cash & equivalents | $8.19M | $419,000 |
| Short-term investments | $1.15M | $6.74M |
| Receivables | $21.20M | $16.43M |
| Inventory | $21.46M | $22.21M |
| Current assets | $53.25M | $47.30M |
| PP&E, net | $5.37M | $5.15M |
| Goodwill | $6.53M | — |
| Intangibles | $686,000 | $26,000 |
| Total assets | $74.51M | $61.19M |
| Current liabilities | $12.98M | $14.63M |
| Long-term debt | $17.51M | $15.43M |
| Total debt | $17.51M | $15.43M |
| Total liabilities | $26.88M | $24.56M |
| Shareholders' equity | $47.63M | $36.63M |
| Net debt | $9.32M | $15.01M |
| Shares outstanding | 3.19M | 3.26M |
| Cash flow statement | ||
| Operating cash flow | $7.24M | -$1.68M |
| Capital expenditure | $483,000 | $1.25M |
| Free cash flow | $6.76M | -$2.93M |
| Investing cash flow | $3.91M | -$238,000 |
| Financing cash flow | -$3.38M | -$292,000 |
| Depreciation & amortization | $1.39M | $1.24M |
| Stock-based compensation | $688,000 | $555,000 |
| Share buybacks | $3.41M | $3.50M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.